There is still plenty to worry about at this year's meeting of the global elite in Davos, from fiscal deficits in the developed world to inflationary risks in emerging markets to new political risks like Egypt.
But with economic recovery taking root in the United States and Germany, while China and India continue to barrel along, company bosses and dealmakers are no longer willing to sit pat.
Overall, multinational companies in developed countries are holding a record $4-5trn in cash, according to a report last week by the United Nations Conference on Trade and Development.
That money was built up as a buffer against a potential double-dip recession, or other systemic shocks, and it is beginning to look like a wasted opportunity.
The mood of confidence – as measured by surveys and conversations with business leaders – is palpably better at this year's annual meeting of the World Economic Forum.
Fair conversations
“Equity valuations are coming back. There are more fair conversations between buyers and sellers,” said one European dealmaker.
“Clearly, cash has to be put to work. It can't just sit on the balance sheet,” said Humana Chief Executive Mike McCallister. “We will continue to look for more opportunities.” He is not alone.
PwC's annual CEO confidence survey, released on Tuesday, showed optimism among CEOs had returned to almost the same level as before the financial crisis, with 48 percent of those questioned very confident about 2011 revenue growth.
Kissing frogs
DSM last month agreed to buy US baby food ingredients maker Martek Biosciences for $1.1bn and, with more than $2.5bn available for acquisitions, Sijbesma hasn't finished shopping yet.
A string of other companies also flagged their interest in acquiring rivals to drive their growth to the next level this week in Davos, including German software maker SAP, French outdoor advertising group JCDecaux, Russia's largest steel producer Severstal, India's No. 2 software exporter Infosys Technologies and Swiss drugmaker Novartis.
Finding the right deal, however, remains as tricky as ever, according to Chris Viehbacher, CEO of French drugmaker Sanofi-Aventis, who is locked in a closely watched takeover battle for US biotech group Genzyme but is also open to other smaller deals.
“You've got to kiss an awful lot of frogs to buy a prince,” he said.
